The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Defining the HBR patient – another step in the right direction

EuroIntervention 2020;16:357-360. DOI: 10.4244/EIJV16I5A64

1. Deutsches Herzzentrum München, Technische Universität München, Munich, Germany; 2. Dublin Cardiovascular Research Institute, Mater Private Hospital, Dublin, Ireland; 3. La Tour Hospital, Geneva, Switzerland

Until recently, patients at high bleeding risk (HBR) were underrepresented in randomised trials of patients undergoing percutaneous coronary intervention (PCI). Lately, however, this important patient population has attracted much attention, with a number of completed and ongoing (NCT03023020; NCT03287167) randomised trials focusing specifically on HBR patients1,2,3,4. While this is a welcome development, the inclusion criteria in such trials have differed considerably. These differences are reflected in the marked variations in major bleeding rates across published trials1,2,3,4,5. Against this background, the Academic Research Consortium for High Bleeding Risk (ARC-HBR) recently proposed criteria to standardise the definition of HBR for use ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
OCT-derived coronary calcified nodules as a predictor of high-risk patients